- Previous Close
1.4400 - Open
1.4510 - Bid 1.3700 x 1000
- Ask 1.4400 x 1000
- Day's Range
1.3500 - 1.4550 - 52 Week Range
1.3500 - 3.9400 - Volume
4,958,409 - Avg. Volume
4,250,910 - Market Cap (intraday)
278.967M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.63
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
www.esperion.com304
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ESPR
View MorePerformance Overview: ESPR
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ESPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ESPR
View MoreValuation Measures
Market Cap
278.97M
Enterprise Value
431.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.79
Price/Book (mrq)
--
Enterprise Value/Revenue
1.30
Enterprise Value/EBITDA
57.05
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.57%
Return on Assets (ttm)
12.37%
Return on Equity (ttm)
--
Revenue (ttm)
332.31M
Net Income Avi to Common (ttm)
-51.74M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
144.76M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.62M